DalsnaFinance

Johnson & Johnson $JNJ

Health Care · Pharmaceuticals · NYSE/NASDAQ

S&P 500 Dow Jones Russell 1000 New Jersey
Create a scorecard
$259.13
+5.17 (+2.04%)
As of Oct 20, 2026, 9:40 AM EDT
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 17, 2026, the first target we tracked for JNJ.

Key facts

52-week range (closes)
$186.00 – $278.43 Lowest close Nov 5, 2025, highest Sep 3, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends
December Fiscal 2025 ended Dec 28, 2025, from SEC filings
In the S&P 500 since
Jun 30, 1973 · All S&P 500 changes
In the Dow since
Mar 17, 1997, replacing Westinghouse Electric, Texaco, Bethlehem Steel and F. W. Woolworth · Travelers Group later became Citigroup. · All Dow changes
Analyst coverage
8 open price targets from 7 firms: RBC Capital Markets, Bank of America, Bernstein, Guggenheim, Raymond James, UBS, Wells Fargo Approved targets tracked here; see the analyst section below

Johnson & Johnson (JNJ) is trading up at $259.13 (+2.04%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on JNJ

Current price targets from 7 firms average $283, median $280, ranging from $270 to $320 — the average is 9% above the current $259. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Johnson & Johnson revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$94.2B$47.1B$0FY2016 revenue: $71.9BFY2016 net income: $16.5B · Net margin 23.0%'16FY2017 revenue: $76.5BFY2017 net income: $1.30B · Net margin 1.7%'17FY2018 revenue: $81.6BFY2018 net income: $15.3B · Net margin 18.8%'18FY2019 revenue: $82.1BFY2019 net income: $15.1B · Net margin 18.4%'19FY2020 revenue: $82.6BFY2020 net income: $14.7B · Net margin 17.8%'20FY2021 revenue: $78.7BFY2021 net income: $20.9B · Net margin 26.5%'21FY2022 revenue: $80.0BFY2022 net income: $17.9B · Net margin 22.4%'22FY2023 revenue: $85.2BFY2023 net income: $35.2B · Net margin 41.3%'23FY2024 revenue: $88.8BFY2024 net income: $14.1B · Net margin 15.8%'24FY2025 revenue: $94.2BFY2025 net income: $26.8B · Net margin 28.5%'250%20%40%60%FY2016 net margin: 23.0%FY2017 net margin: 1.7%FY2018 net margin: 18.8%FY2019 net margin: 18.4%FY2020 net margin: 17.8%FY2021 net margin: 26.5%FY2022 net margin: 22.4%FY2023 net margin: 41.3%FY2024 net margin: 15.8%FY2025 net margin: 28.5%
Johnson & Johnson annual financial statements
FY2016Jan 2017FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Jan 2021FY2021Jan 2022FY2022Jan 2023FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$71.9B$76.5B$81.6B$82.1B$82.6B$78.7B$80.0B$85.2B$88.8B$94.2B
Growth (year over year)+2.6%+6.3%+6.7%+0.6%+0.6%−4.7%+1.6%+6.5%+4.3%+6.0%
Gross profit$50.1B$51.0B$54.5B$54.5B$54.2B$55.3B$55.4B$58.6B$61.4B$63.9B
Gross margin69.7%66.7%66.8%66.4%65.6%70.3%69.3%68.8%69.1%67.9%
Net income$16.5B$1.30B$15.3B$15.1B$14.7B$20.9B$17.9B$35.2B$14.1B$26.8B
Net margin23.0%1.7%18.8%18.4%17.8%26.5%22.4%41.3%15.8%28.5%
EPS (diluted)$5.93$0.47$5.61$5.63$5.51$7.81$6.73$13.72$5.79$11.03
Balance sheet
Cash and equivalents$19.0B$17.8B$18.1B$17.3B$14.0B$14.5B$12.9B$21.9B$24.1B$19.7B
Total assets$141.2B$157.3B$153.0B$157.7B$174.9B$182.0B$187.4B$167.6B$180.1B$199.2B
Total liabilities$70.8B$97.1B$93.2B$98.3B$111.6B$108.0B$110.6B$98.8B$108.6B$117.7B
Long-term debt$22.4B$30.7B$27.7B$26.5B$32.6B$30.0B$26.9B$25.9B$30.7B$39.4B
Shareholders' equity$70.4B$60.2B$59.8B$59.5B$63.3B$74.0B$76.8B$68.8B$71.5B$81.5B
Cash flow
Operating cash flow$18.8B$21.1B$22.2B$23.4B$23.5B$23.4B$21.2B$22.8B$24.3B$24.5B
Capital expenditure$3.23B$3.28B$3.67B$3.50B$3.35B$3.65B$4.01B$4.54B$4.42B$4.83B
Free cash flow$15.5B$17.8B$18.5B$19.9B$20.2B$19.8B$17.2B$18.2B$19.8B$19.7B
Share buybacks$8.98B$6.36B$5.87B$6.75B$3.22B$3.46B$6.04B$5.05B$2.43B$5.95B

From Johnson & Johnson's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Johnson & Johnson vs the Health Care sector and the S&P 500

Johnson & Johnson's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Johnson & Johnson compared with the median Health Care company and the median S&P 500 company
MeasureJohnson & JohnsonHealth Care (59 other S&P 500 companies)S&P 500 (502 other companies)
Revenue growth, latest fiscal year+6.0%+7.2%+7.0%
Net margin, latest fiscal year28.5%12.9%12.9%
Dividend per share, latest fiscal year$5.14$2.43$2.40
Share price change, 1 year+31.0%+19.8%+5.6%

Johnson & Johnson: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Johnson & Johnson included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.

About Johnson & Johnson

Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.

Source: Wikipedia — Johnson & Johnson

Headquarters
New Brunswick, New Jersey From SEC filings, Oct 2026

Recent News (20)

More Health Care stocks

Browse all companies →